Programs
CandidateCand | IndicationInd | DiscoveryDisc | PreclinicalPre | Phase 1Ph1 | Phase 2Ph2 | Phase 3Ph3 | PartnersPart |
|---|---|---|---|---|---|---|---|
Furmonertinib | |||||||
Oral, brain penetrant, EGFR mutation selective inhibitor |
FurmonertinibOral, brain penetrant, EGFR mutation selective inhibitor | ||||||
ARR-002 | |||||||
Undisclosed |
ARR-002Undisclosed | ||||||